Ki-67 and AgNOR might be useful as a prognostic marker in KCOTs. A standard protocol needed for the evaluation of AgNORs. The positive correlation of these markers reinforced the neoplastic character of the KCOT. The higher expression of these markers in recurrent lesions is important in order to consider additional surgical interventions to improve prognosis..
GlucoTrack performance was evaluated using clinical and numerical accuracy methods [28]. Clinical accuracy was assessed using Clarke error grid (CEG) analysis that evaluates medical importance of the differentiations between GlucoTrack and the established invasive blood glucose reference method [29]. In this analysis, a grid breaks down a scatterplot of a reference glucose monitoring device and an evaluated glucose monitoring device into five regions: region A includes values within 20% of the reference, region B contains points that are outside of 20% but would not lead to inappropriate treatment, region C consists of points leading to unnecessary treatment, region D includes points indicating a potentially dangerous failure to detect hypoglycemia or hyperglycemia, and region E contains points that would confuse treatment of hypoglycemia for hyperglycemia and vice versa. Region A is considered clinically accurate and region B is considered clinically acceptable. Numerical accuracy was assessed using absolute relative difference (ARD) of paired GlucoTrack-HemoCue measurement readings, calculated as follows: ARD=